• Breakthrough Composition of Matter IP filed for bisantrene, providing 20 years of protection
• Advance of Phase 1 trial of RC220 with two patients safely treated
• Ongoing disciplined capital management, with $11.27m cash balance at quarter end

Race Oncology Ltd released its Q1 FY2026 report for the period ending 30 September 2025. The company announced a major IP breakthrough with the discovery and filing of three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-isoform of bisantrene. This discovery significantly changes the commercial outlook for Race, with the potential to provide 20 years of composition of matter protection. The Race clinical team continued to progress the Phase 1 cardioprotection and anticancer clinical trial of RC220 in combination with doxorubicin, with two patients safely treated during the quarter. Additional sites in Hong Kong and South Korea received ethics and regulatory approval, with increased patient recruitment expected in Q2 FY2026. Race's cash and cash equivalents totalled $11.27 million as of the end of the quarter, with more than 78% of spending directed toward R&D and drug manufacturing activities. Early conversion of options by shareholders has provided an additional $3.6 million of funding, placing Race in an excellent position to fund all announced activities through CY2026.